市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 混合的 | |
| 股票 | OptiNose, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
-0.1
| 分析师共识 | -3.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.13 |
|
OptiNose Inc is a specialty pharmaceutical company focuses on the development and commercialization of products for patients treated by ear, nose, and throat (ENT), and allergy specialists. Its first commercial product, XHANCE (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing the proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Value |
| 内部持股比例 | 6.21% |
| 机构持股比例 | 78.44% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mvm Partners, Llc | 30 Sep 2024 | 973,733 |
| Great Point Partners I Lp | 30 Sep 2024 | 857,452 |
| Rosalind Advisors, Inc. | 30 Sep 2024 | 552,528 |
| Bleichroeder Lp | 30 Sep 2024 | 269,689 |
| Easterly Investment Partners Llc | 30 Sep 2024 | 157,290 |
| Velan Capital Investment Management Lp | 30 Sep 2024 | 143,114 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 18.00 (HC Wainwright & Co., 175.02%) | 购买 |
| 中 | 9.50 (45.15%) | |
| 低 | 1.00 (Piper Sandler, -84.72%) | 购买 |
| 平均值 | 9.50 (45.15%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 7.07 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| HC Wainwright & Co. | 03 Jan 2025 | 18.00 (175.02%) | 购买 | 6.54 |
| 13 Nov 2024 | 5.00 (-23.61%) | 购买 | 7.61 | |
| Piper Sandler | 13 Nov 2024 | 1.00 (-84.72%) | 购买 | 7.61 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 26 Dec 2024 | 公告 | Optinose Announces 1-for-15 Reverse Stock Split |
| 02 Dec 2024 | 公告 | Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference |
| 12 Nov 2024 | 公告 | Optinose Reports Third Quarter 2024 Financial Results and Recent Operational Highlights |
| 05 Nov 2024 | 公告 | Optinose Announces Reporting Date for Third Quarter 2024 Financial Results |
| 16 Oct 2024 | 公告 | Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 07 Oct 2024 | 公告 | Optinose Appoints Terry Kohler as Chief Financial Officer |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合